Once-weekly dosing of Kyprolis improves PFS vs. twice-weekly option

Amgen Inc. (NASDAQ:AMGN) reported interim data from the Phase III ARROW trial in 478 patients with relapsed and refractory multiple myeloma (MM) showing that 70 mg/m² Kyprolis carfilzomib (ONO-7057, PR-171) administered once weekly led to a progression-free survival (PFS) of 11.2 months vs. 7.6 months for 27 mg/m² Kyprolis administered twice weekly (HR=0.39, 95% CI: 0.54, 0.88). The most common treatment-related adverse events reported were anemia, diarrhea, fatigue, hypertension, insomnia and pyrexia.

The open-label, U.S. trial’s primary endpoint is PFS. Secondary endpoints include overall response rate (ORR), overall survival (OS), pharmacokinetics and safety...